At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 421 enrolled
Drug / intervention
Enbrel (etanercept) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-injector and the Etanercept Prefilled Syringe) in Patients With Psoriasis.
In Brief
A Phase 3 clinical trial evaluating Enbrel (etanercept) and Etanercept for Psoriasis. Completed, enrolled 421 participants across 78 sites in 12 countries.
Detailed Summary
Primary objective of this study is to compare patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI), two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form totally dissatisfied to totally satisfied.Secondary evaluation focus on the identification of patient and device attributes associated with patient satisfaction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesBelgium, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartSep 2007
Primary CompletionApr 2009
Study CompletionSep 2009
TodayJul 2026
First PostedJun 4, 2007
Enrollment StartSep 1, 2007
Primary CompletionApr 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.1 years ago
Interventions
Enbrel (etanercept)device
Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
Etanerceptdevice
Arm 2 = Enbrel 50 mg Autoinjector twice weekly